Gene variant reduces cholesterol by two mechanisms

July 2, 2012

High levels of low-density lipoprotein (LDL) cholesterol increases the risk for coronary heart disease.

A variant in the encoding the protein sortilin is associated with reduced plasma LDL levels and a decreased risk of heart attack.

This variant results in markedly higher sortilin in liver.

Dr. Daniel Rader and colleagues at the University of Pennsylvania in Philadelphia have uncovered a two-pronged mechanism for the change in LDL observed.

Using a mouse model system, the Rader team found that increased liver sortilin is responsible for reducing secretion of APOB, a protein that transports LDL to tissue, and also triggers LDL breakdown.

Both of these effects were dependent on a cellular process known as lysosomal targeting.

Their data provide functional evidence that genetically-increased hepatic sortilin in humans reduces LDL by increasing LDL degradation, thus removing LDL from circulation, as well as decreasing APOB.

Explore further: Non-HDL-C level associated with risk of major cardiovascular events among patients taking statins

More information: Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism, Journal of Clinical Investigation.

Related Stories

Recommended for you

Resveratrol may be an effective intervention for lung aging

February 22, 2017

In a study led by Barbara Driscoll, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, researchers demonstrate, for the first time that inhaled resveratrol treatments slow aging-related degenerative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.